Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

BACKGROUND Metastatic prostate cancer is a leading cause of cancer-related death in men. The rate of response to androgen ablation is high, but most patients relapse as a result of the outgrowth of androgen-independent tumor cells. The androgen receptor, which binds testosterone and stimulates the transcription of androgen-responsive genes, regulates the growth of prostate cells. We analyzed the androgen-receptor genes from samples of metastatic androgen-independent prostate cancers to determine whether mutations in the gene have a role in androgen independence. METHODS Complementary DNA was synthesized from metastatic prostate cancers in 10 patients with androgen-independent prostate cancer, and the expression of the androgen-receptor gene was estimated by amplification with the polymerase chain reaction. Exons B through H of the gene were cloned, and mutations were identified by DNA sequencing. The functional effects of the mutations were assessed in cells transfected with mutant genes. RESULTS All androgen-independent tumors expressed high levels of androgen-receptor gene transcripts, relative to the levels expressed by an androgen-independent prostate-cancer cell line (LNCaP). Point mutations in the androgen-receptor gene were identified in metastatic cells from 5 of the 10 patients examined. One mutation was in the same codon as the mutation found previously in the androgen-independent prostate-cancer cell line. The mutations were not detected in the primary tumors from of the two patients. Functional studies of two of the mutant androgen receptors demonstrated that they could be activated by progesterone and estrogen. CONCLUSIONS Most metastatic androgen-independent prostate cancers express high levels of androgen-receptor gene transcripts. Mutations in androgen-receptor genes are not uncommon and may provide a selective growth advantage after androgen ablation.

[1]  F. S. French,et al.  The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. , 1988, Molecular endocrinology.

[2]  O. Dalesio,et al.  Systematic overview (metaanalysis) of all randomized trials of treatment of prostate cancer , 1993, Cancer.

[3]  D. Nelson,et al.  Triplet repeat mutations in human disease. , 1992, Science.

[4]  H. Klocker,et al.  DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction , 1993, The Prostate.

[5]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[6]  C. Wilson,et al.  Definition of the human androgen receptor gene structure permits the identification of mutations that cause androgen resistance: premature termination of the receptor protein at amino acid residue 588 causes complete androgen resistance. , 1990, Molecular endocrinology.

[7]  J. A. van der Korput,et al.  The human androgen receptor: domain structure, genomic organization and regulation of expression. , 1989, Journal of steroid biochemistry.

[8]  S. Balk,et al.  Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain , 1993, The Journal of experimental medicine.

[9]  Gene regulation by steroid hormones , 1989, Cell.

[10]  F. S. French,et al.  Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Crawford.  Challenges in the management of prostate cancer. , 1992, British journal of urology.

[12]  N. Sato,et al.  Androgen receptor gene mutations in human prostate cancer , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  T. H. van der Kwast,et al.  Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. , 1991, Molecular endocrinology.

[14]  S. J. Higgins,et al.  The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.

[15]  G. T. Budd,et al.  Estrogen receptor mutations in tamoxifen-resistant breast cancer. , 1994, Cancer research.

[16]  M. Colombel,et al.  Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. , 1992, Cancer research.

[17]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. S. French,et al.  Autologous down-regulation of androgen receptor messenger ribonucleic acid. , 1990, Molecular endocrinology.

[19]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.

[20]  T. H. van der Kwast,et al.  Androgen receptors in endocrine‐therapy‐resistant human prostate cancer , 1991, International journal of cancer.

[21]  L. Hoffman,et al.  Autoimmune disease and silicone breast implants. , 1993, Oncology.

[22]  Schr,et al.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[23]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[24]  P. Riegman,et al.  The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. , 1991, Molecular endocrinology.

[25]  S. Nordeen,et al.  Luciferase reporter gene vectors for analysis of promoters and enhancers. , 1988, BioTechniques.

[26]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[27]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  W. McGuire,et al.  Estrogen receptor mutations in breast cancer , 1993, Journal of cellular biochemistry.

[29]  I. Ginjaar,et al.  The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. , 1987, Journal of immunology.

[30]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[31]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[32]  T. Tong,et al.  Cancer statistics, 1992 , 1992, CA: a cancer journal for clinicians.